{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:06:55Z","timestamp":1783498015012,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.berh.2019.03.011","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T11:16:51Z","timestamp":1555327011000},"page":"869-886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management"],"prefix":"10.1016","volume":"32","author":[{"given":"Diederik","family":"De Cock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review","volume":"36","author":"Alamanos","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"10055","key":"10.1016\/j.berh.2019.03.011_bib2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isomaki","year":"1978","journal-title":"J\u00a0Chronic Dis"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2019.03.011_bib5","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A\u00a0meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.03.011_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2019.03.011_bib7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.011_bib8","series-title":"American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting","first-page":"359","article-title":"Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer","author":"Warren","year":"2013"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.2008.096487","article-title":"Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies","volume":"69","author":"Sugiyama","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib10","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib11","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/art.27402","article-title":"Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis","volume":"62","author":"Hellgren","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2019.03.011_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/gut.2009.203000","article-title":"Effect of aspirin and NSAIDs on risk and survival from colorectal cancer","volume":"59","author":"Din","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib14","first-page":"551","article-title":"Low incidence of colorectal cancer in patients with rheumatoid arthritis","volume":"14","author":"Kauppi","year":"1996","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib17","first-page":"CD000957","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2019.03.011_bib18","doi-asserted-by":"crossref","first-page":"4609486","DOI":"10.1155\/2016\/4609486","article-title":"Risk of malignant neoplasm in patients with incident rheumatoid arthritis 1980-2007 in relation to a comparator cohort: a population-based study","volume":"2016","author":"Raheel","year":"2016","journal-title":"Int J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2019.03.011_bib20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/acr.22306","article-title":"Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients","volume":"66","author":"Kameda","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0896-8411(89)80010-1","article-title":"The risk of neoplasms in patients treated with cyclosporine A","volume":"2","author":"Cockburn","year":"1989","journal-title":"J\u00a0Autoimmun"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2019.03.011_bib22","first-page":"72","article-title":"Malignancies in rheumatoid arthritis patients treated with cyclosporin A","volume":"32","author":"Arellano","year":"1993","journal-title":"Br J Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N","article-title":"No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis","volume":"41","author":"van den Borne","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib24","first-page":"421","article-title":"Cyclosporin-A associated malignancy","volume":"1","author":"Durnian","year":"2007","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"J\u00a0Dermatol Treat"},{"issue":"2","key":"10.1016\/j.berh.2019.03.011_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00124743-199604000-00002","article-title":"Lymphoma and leukemia in rheumatoid arthritis: are they associated with azathioprine, cyclophosphamide, or methotrexate?","volume":"2","author":"Williams","year":"1996","journal-title":"J\u00a0Clin Rheumatol \u2013 Practical Rep Rheum Musculoskel Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/rheumatology\/keq301","article-title":"Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers","volume":"50","author":"Strangfeld","year":"2011","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2019.03.011_bib29","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","article-title":"Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry","volume":"54","author":"Gabay","year":"2015","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.berh.2019.03.011_bib31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.berh.2019.03.011_bib32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2019.03.011_bib33","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib34","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2019.03.011_bib35","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.30247","volume":"63","author":"Raaschou","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2019.03.011_bib38","doi-asserted-by":"crossref","first-page":"e6055","DOI":"10.1097\/MD.0000000000006055","article-title":"Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-alpha inhibitor","volume":"96","author":"Lan","year":"2017","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/rheumatology\/keu446","article-title":"The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers","volume":"54","author":"Kearsley-Fleet","year":"2015","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2019.03.011_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrrheum.2017.81","article-title":"Biologics registers in RA: methodological aspects, current role and future applications","volume":"13","author":"Nikiphorou","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib41","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/ard.2005.045872","article-title":"Swedish registers to examine drug safety and clinical issues in RA","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.011_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib43","first-page":"58","article-title":"The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy","volume":"1","author":"Watson","year":"2003","journal-title":"Muscoskel Care"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib44","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/rheumatology\/ken242","article-title":"The British society for Rheumatology biologics register: 6 years on","volume":"47","author":"Hyrich","year":"2008","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2019.03.011_bib45","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/ard.2004.031476","article-title":"Treatment continuation in patients receiving biological agents or conventional DMARD therapy","volume":"64","author":"Zink","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib46","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib47","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2019.03.011_bib48","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib50","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2019.03.011_bib51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib52","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study","volume":"108","author":"Deepak","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib55","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2019.03.011_bib57","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/annrheumdis-2015-208263","article-title":"Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden","volume":"75","author":"Wadstrom","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2019.03.011_bib59","unstructured":"SPC Enbrel. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf. Last accessed 11\/04\/2019."},{"issue":"8","key":"10.1016\/j.berh.2019.03.011_bib60","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.berh.2019.03.011_bib61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.berh.2019.03.011_bib62","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib63","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib64","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J\u00a0Clin Oncol \u2013 Offi J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.berh.2019.03.011_bib65","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1136\/annrheumdis-2017-212205","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis","volume":"77","author":"Olsen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib66","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"issue":"23","key":"10.1016\/j.berh.2019.03.011_bib67","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib68","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10 Suppl 8","key":"10.1016\/j.berh.2019.03.011_bib70","first-page":"63","article-title":"Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies","volume":"12","author":"Maloney","year":"1998","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib71","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years","volume":"42","author":"van Vollenhoven","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib73","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jbspin.2010.11.012","article-title":"Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort","volume":"78","author":"Slimani","year":"2011","journal-title":"Joint Bone Spine \u2013 revue du rhumatisme."},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib74","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Anti-rheumatic therapy in Sweden study G. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.berh.2019.03.011_bib75","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","article-title":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","volume":"68","author":"Simon","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib76","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/s10165-010-0279-5","article-title":"Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions","volume":"20","author":"Nishimoto","year":"2010","journal-title":"Mod Rheumatol\/Jpn Rheum Assoc"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib77","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib78","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2019.03.011_bib79","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.38687","article-title":"Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment","volume":"66","author":"Alten","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2019.03.011_bib80","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.03.011_bib81","first-page":"553","article-title":"Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study","volume":"32","author":"Westhovens","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib82","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/14397595.2015.1012786","article-title":"Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders","volume":"25","author":"Amano","year":"2015","journal-title":"Mod Rheumatol\/Jpn Rheum Assoc"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib83","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib84","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","article-title":"Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis","volume":"5","author":"Cohen","year":"2018","journal-title":"Rheumatology Ther"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib85","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10067-018-4199-7","article-title":"Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials","volume":"37","author":"Kunwar","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"9916","key":"10.1016\/j.berh.2019.03.011_bib86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(13)62224-2","article-title":"Global cancer patterns: causes and prevention","volume":"383","author":"Vineis","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib87","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/rheumatology\/kew314","article-title":"The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis","volume":"55","author":"Silva-Fernandez","year":"2016","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.7326\/M17-2812","article-title":"Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study","volume":"169","author":"Raaschou","year":"2018","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143286","article-title":"Tumor necrosis factor inhibition and head and neck cancer recurrence and death in rheumatoid arthritis","volume":"10","author":"Phillips","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.berh.2019.03.011_bib90","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/annrheumdis-2014-205745","article-title":"TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study","volume":"74","author":"Raaschou","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2019.03.011_bib91","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/art.39738","article-title":"Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study","volume":"68","author":"Mamtani","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2019.03.011_bib92","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","article-title":"Addressing the issue of channeling bias in observational studies with propensity scores analysis","volume":"2","author":"Lobo","year":"2006","journal-title":"Res Soc Adm Pharm \u2013 RSAP"},{"issue":"5","key":"10.1016\/j.berh.2019.03.011_bib93","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/annrheumdis-2017-212395","article-title":"Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics","volume":"77","author":"Frisell","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib94","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"19","key":"10.1016\/j.berh.2019.03.011_bib95","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.berh.2019.03.011_bib96","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","article-title":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.03.011_bib97","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","article-title":"BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies","volume":"49","author":"Ding","year":"2010","journal-title":"Rheumatology"},{"issue":"Suppl 10","key":"10.1016\/j.berh.2019.03.011_bib98","article-title":"Treatment decisions following diagnosis of cancer during TNFi inhibitor treatment in patients with rheumatoid arthritis: results from the BSRBR-RA [abstract]","volume":"68","author":"Druce","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.03.011_bib99","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2019.03.011_bib100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA dermatology"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:18:53Z","timestamp":1761499133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521694219300464"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.03.011","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}